Accuray
(Nasdaq: ARAY)
announced today that it received CE mark approval for its Helix CT-guided helical radiotherapy system.
The Madison, Wisconsin-based company designed Helix to deliver high performance and high throughput in radiotherapy. It developed the new system for emerging markets in which access to advanced cancer care — including radiotherapy — is typically obtainable only within urban areas. These areas have an availability of linear accelerators per million population well under World Health Organization recommended guidelines. The company labeled India as a priority due to this disparity as well.
Accuray Helix provides a solution for clinical teams requiring short treatment times and cost-effectiveness. The company wants to establish a care path for patients in non-urban communities who previously faced limited options.
According to a news release, Accuray Helix delivers precise, targeted radiation treatments. It provides an option for routine cases, including in the breast, cervix, head and neck, gastrointestinal, lung and prostate. Accuray wants its system’s flexibility and versatility to drive improvements in personalization and patient care.
Helix could facilitate more treatments each day. The system would help clinics efficiently manage the growing demand for cancer care.
“While the demand for cancer services is increasing globally, there are certain areas of the world where there continues to be greater gaps in access to radiation medicine,” said Suzanne Winter, Accuray president and CEO. “Our goal with the introduction of Accuray Helix is to close some of these gaps to patient access with our comprehensive solutions. The Accuray Helix system combines affordability with automation and tools for enhancing the speed of planning and delivery of radiation.
“We believe it will enable a broader range of capabilities for facilities that may have resources and staffing for only one system, enabling them to offer state-of-the-art cancer care in their communities.”
